The 2025 lung cancer landscape: advances in screening, molecular taxonomy and therapeutic strategy: a narrative review

作者：Wenhai Fu, Xusen Zou, Tianrui He, Qi Cai, Peiling Chen, B. Cheng, Yi Feng, Caichen Li, Feng Li, Jianfu Li, Huiting Wang, S. Xiong, Wenjun Ye, Xin Zheng, Jianxing He, Wenhua Liang · 发表于：Translational Lung Cancer Research · 年份：2026 · DOI：10.21037/tlcr-2025-1-1477 · 研究领域：Lung Cancer Research Studies、Lung Cancer Diagnosis and Treatment、Cancer Immunotherapy and Biomarkers

Background and Objective: In 2025, lung cancer research advanced rapidly across the disease continuum, from population-level risk assessment and screening to mechanistic studies of early carcinogenesis and therapeutic innovation in perioperative and metastatic settings. A key shift moved beyond a smoking-centred paradigm toward a multidimensional risk framework reflecting the growing burden among never-smokers and the roles of air pollution, occupational exposures, and systemic metabolic-inflammatory states. This narrative review aims to synthesize influential 2025 evidence across prevention, diagnosis, treatment, and survivorship, and to identify convergent themes and translational gaps relevant to clinical practice and policy. Methods: We performed a narrative synthesis of influential lung cancer studies published in major international journals in 2025. Evidence was organized along a clinically oriented pathway spanning carcinogenesis and screening, precision diagnosis, treatment optimization in resectable and advanced disease, and survivorship, emphasizing practice-informing trials, high-impact translational research, and implementation-relevant technologies. Key Content and Findings: Lineage tracing, single-cell and spatial omics, and evolutionary inference refined concepts of field cancerization, clonal selection, and copy-number-driven fitness. In small-cell lung cancer, evidence further supported neuronal coupling and synapse-like programs as potentially tractable vul...